Cargando…

Doxorubicin Conjugation to Reovirus Improves Oncolytic Efficacy in Triple-Negative Breast Cancer

Breast cancer is the second leading cause of cancer-related deaths in women in the United States. The triple-negative breast cancer (TNBC) subtype associates with higher rates of relapse, shorter overall survival, and aggressive metastatic disease. Hormone therapy is ineffective against TNBC, leavin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Berry, Jameson T.L., Muñoz, Luis E., Rodríguez Stewart, Roxana M., Selvaraj, Periasamy, Mainou, Bernardo A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Gene & Cell Therapy 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7493048/ https://www.ncbi.nlm.nih.gov/pubmed/32995480 http://dx.doi.org/10.1016/j.omto.2020.08.008

Ejemplares similares

Current understanding of reovirus oncolysis mechanisms
por: Phillips, Matthew B, et al.
Publicado: (2018)

The Orchestra of Reovirus Cell Entry
por: Mainou, Bernardo A.
Publicado: (2017)

Past, Present and Future of Oncolytic Reovirus
por: Müller, Louise, et al.
Publicado: (2020)

Bacteria and bacterial envelope components enhance mammalian reovirus thermostability
por: Berger, Angela K., et al.
Publicado: (2017)

From Touchdown to Transcription: The Reovirus Cell Entry Pathway
por: Danthi, Pranav, et al.
Publicado: (2010)

Oncolytic Reovirus in Canine Mast Cell Tumor
por: Hwang, Chung Chew, et al.
Publicado: (2013)

Oncolytic Reovirus Infection Is Facilitated by the Autophagic Machinery
por: Kemp, Vera, et al.
Publicado: (2017)

Directional Release of Reovirus from the Apical Surface of Polarized Endothelial Cells
por: Lai, Caroline M., et al.
Publicado: (2013)

Reovirus Cell Entry Requires Functional Microtubules
por: Mainou, Bernardo A., et al.
Publicado: (2013)

Anti-tumor efficacy of oncolytic reovirus against gastrointestinal stromal tumor cells
por: Inagaki, Yusuke, et al.
Publicado: (2017)

Oncolytic activity of reovirus in HPV positive and negative head and neck squamous cell carcinoma
por: Cooper, Timothy, et al.
Publicado: (2015)

The oncolytic effect in vivo of reovirus on tumour cells that have survived reovirus cell killing in vitro
por: Alain, T, et al.
Publicado: (2006)

Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer
por: Heinemann, Lucy, et al.
Publicado: (2011)

The oncolytic effects of reovirus in canine solid tumor cell lines
por: IGASE, Masaya, et al.
Publicado: (2015)

Exploring Reovirus Plasticity for Improving Its Use as Oncolytic Virus
por: Kemp, Vera, et al.
Publicado: (2015)

Role of Myeloid Cells in Oncolytic Reovirus-Based Cancer Therapy
por: Kumar, Vishnupriyan, et al.
Publicado: (2021)

Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model
por: Camilio, Ketil A., et al.
Publicado: (2019)

Oncolytic viruses for triple negative breast cancer and beyond
por: Jin, Shengye, et al.
Publicado: (2021)

Targeting Triple Negative Breast Cancer With Oncolytic Adenoviruses
por: Green-Tripp, Gabriela, et al.
Publicado: (2022)

Cytokine-induced killer cell delivery enhances the antitumor activity of oncolytic reovirus
por: Zhao, Xing, et al.
Publicado: (2017)

Reovirus Forms Neo-Organelles for Progeny Particle Assembly within Reorganized Cell Membranes
por: Fernández de Castro, Isabel, et al.
Publicado: (2014)

Clinical trials with oncolytic reovirus: Moving beyond phase I into combinations with standard therapeutics
por: Harrington, K.J., et al.
Publicado: (2010)

Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer
por: Samson, Adel, et al.
Publicado: (2018)

Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy
por: Kelly, Kevin R., et al.
Publicado: (2017)

Oncolytic Reovirus and Immune Checkpoint Inhibition as a Novel Immunotherapeutic Strategy for Breast Cancer
por: Mostafa, Ahmed A., et al.
Publicado: (2018)

Correction: Cytokine-induced killer cell delivery enhances the antitumor activity of oncolytic reovirus
por: Zhao, Xing, et al.
Publicado: (2018)

Kinetics of Oncolytic Reovirus T3D Replication and Growth Pattern in Mesenchymal Stem Cells
por: Banijamali, Razieh Sadat, et al.
Publicado: (2020)

IL-17A Increases Doxorubicin Efficacy in Triple Negative Breast Cancer
por: Hum, Nicholas R., et al.
Publicado: (2022)

Reovirus infection is regulated by NPC1 and endosomal cholesterol homeostasis
por: Ortega-Gonzalez, Paula, et al.
Publicado: (2022)

Reovirus σNS and μNS Proteins Remodel the Endoplasmic Reticulum to Build Replication Neo-Organelles
por: Tenorio, Raquel, et al.
Publicado: (2018)

Preinduced reovirus-specific T-cell immunity enhances the anticancer efficacy of reovirus therapy
por: Groeneveldt, Christianne, et al.
Publicado: (2022)

Oncolytic reovirus preferentially induces apoptosis in KRAS mutant colorectal cancer cells, and synergizes with irinotecan
por: Maitra, Radhashree, et al.
Publicado: (2014)

Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus
por: Kelly, Kevin R., et al.
Publicado: (2015)

Altered Glycan Expression on Breast Cancer Cells Facilitates Infection by T3 Seroptype Oncolytic Reovirus
por: Mohammed, Danahe, et al.
Publicado: (2021)

High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer
por: Torres-Ruiz, Sandra, et al.
Publicado: (2023)

HDAC Inhibitors Enhance Efficacy of the Oncolytic Adenoviruses Ad∆∆ and Ad-3∆-A20T in Pancreatic and Triple-Negative Breast Cancer Models
por: Rodríguez, María Del Carmen Rodríguez, et al.
Publicado: (2022)

Triple-Negative Breast Cancer: Basic Biology and Immuno-Oncolytic Viruses
por: Monaco, Michael L., et al.
Publicado: (2023)

Evaluation of a Keratin 1 Targeting Peptide-Doxorubicin Conjugate in a Mouse Model of Triple-Negative Breast Cancer
por: Saghaeidehkordi, Azam, et al.
Publicado: (2021)

Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells
por: Sei, Shizuko, et al.
Publicado: (2009)

Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia
por: Parrish, C, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_lrhpgv519l9fansmh4m4tdufuc